Bcl-w inhib Trials - LARVOL Sigma

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

navitoclax (ABT 263) / AbbVie

TRANSFORM-1, NCT04472598 / 2020-000097-15: Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis

	Jan 2024 - Dec 2024: Approval for 1L myelofibrosis (based on TRANSFORM-1 trial)
	Jan 2023 - Dec 2023: Data readout from TRANSFORM-1 trial in combination with Jakafi oral for myelofibrosis

Active, not recruiting

252

Europe, Canada, Japan, US, RoW

Navitoclax, ABT-263, Ruxolitinib, Placebo for Navitoclax

AbbVie

Myelofibrosis (MF)

04/23

01/25

TRANSFORM-2, NCT04468984 / 2020-000557-27: Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis

	Jan 2024 - Dec 2024: Submission for r/r myeloﬁbrosis in combination with Jakafi (based on TRANSFORM-2 trial)
	Jan 2024 - Dec 2024: Data readout from TRANSFORM-2 trial in combination with ruxolitinib for r/r myeloﬁbrosis

Active, not recruiting

295

Europe, Canada, Japan, US, RoW

Navitoclax, ABT-263, Ruxolitinib, Best Available Therapy (BAT)

AbbVie

Myelofibrosis (MF)

01/25

REFINE, NCT03222609 / 2017-001398-17: A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Participants With Myelofibrosis

	Data from P2 REFINE trial for myeloﬁbrosis
	Dec 2022 - Dec 2022: Data from P2 REFINE trial for myeloﬁbrosis
	Data from P2 REFINE trial in combination with ruxolitinib in JAK inhibitor-naïve myelofibrosis at ASH 2022
	Dec 2022 - Dec 2022: Data from P2 REFINE trial in combination with ruxolitinib in JAK inhibitor-naïve myelofibrosis at ASH 2022

Active, not recruiting

191

Europe, Canada, Japan, US, RoW

Ruxolitinib, Jakafi, Navitoclax, ABT-263

AbbVie

Myelofibrosis (MF)

03/22

01/25

NCT06210750: Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL)

Withdrawn

154

Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Calaspargase Pegol, Asparaginase (Escherichia coli Isoenzyme II), Conjugate with alpha-(((2,5-Dioxo-1-pyrrolidinyl)oxy)carbonyl)-omega-methoxypoly(oxy-1,2-ethanediyl), Asparlas, Calaspargase Pegol-mknl, EZN-2285, SC-PEG E. Coli L-Asparaginase, Succinimidyl Carbonate Monomethoxypolyethylene Glycol E. coli L-Asparaginase, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Asta B 518, B-518, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, WR-138719, Cytarabine, .beta.-Cytosine arabinoside, 1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-.beta.-D-Arabinofuranosylcytosine, 1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-Beta-D-arabinofuranosylcytosine, 1.beta.-D-Arabinofuranosylcytosine, 2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-, 2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-, Alexan, Ara-C, ARA-cell, Arabine, Arabinofuranosylcytosine, Arabinosylcytosine, Aracytidine, Aracytin, Aracytine, Beta-Cytosine Arabinoside, CHX-3311, Cytarabinum, Cytarbel, Cytosar, Cytosine Arabinoside, Cytosine-.beta.-arabinoside, Cytosine-beta-arabinoside, Erpalfa, Starasid, Tarabine PFS, U 19920, U-19920, Udicil, WR-28453, Daunorubicin, Daunomycin, Daunorrubicina, DNR, Leukaemomycin C, Rubidomycin, Rubomycin C, Dexamethasone, Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin, Alin Depot, Alin Oftalmico, Amplidermis, Anemul mono, Auricularum, Auxiloson, Baycadron, Baycuten, Baycuten N, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decadron DP, Decalix, Decameth, Decasone R.p., Dectancyl, Dekacort, Deltafluorene, Deronil, Desamethasone, Desameton, Dexa-Mamallet, Dexa-Rhinosan, Dexa-Scheroson, Dexa-sine, Dexacortal, Dexacortin, Dexafarma, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasone Intensol, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Dexone, Dinormon, Dxevo, Fluorodelta, Fortecortin, Gammacorten, Hemady, Hexadecadrol, Hexadrol, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, TaperDex, Visumetazone, ZoDex, Doxorubicin, Adriablastin, Hydroxydaunomycin, Hydroxyl Daunorubicin, Hydroxyldaunorubicin, Echocardiography, EC, Lumbar Puncture, LP, Spinal Tap, Mercaptopurine, 3H-Purine-6-thiol, 6 MP, 6 Thiohypoxanthine, 6 Thiopurine, 6-Mercaptopurine, 6-Mercaptopurine Monohydrate, 6-MP, 6-Purinethiol, 6-Thiopurine, 6-Thioxopurine, 6H-Purine-6-thione, 1,7-dihydro- (9CI), 7-Mercapto-1,3,4,6-tetrazaindene, Alti-Mercaptopurine, Azathiopurine, Bw 57-323H, Flocofil, Ismipur, Leukerin, Leupurin, Mercaleukim, Mercaleukin, Mercaptina, Mercaptopurinum, Mercapurin, Mern, NCI-C04886, Puri-Nethol, Purimethol, Purine, 6-mercapto-, Purine-6-thiol (8CI), Purine-6-thiol, monohydrate, Purinethiol, Purinethol, U-4748, WR-2785, Methotrexate, Abitrexate, Alpha-Methopterin, Amethopterin, Brimexate, CL 14377, CL-14377, Emtexate, Emthexat, Emthexate, Farmitrexat, Fauldexato, Folex, Folex PFS, Lantarel, Ledertrexate, Lumexon, Maxtrex, Medsatrexate, Metex, Methoblastin, Methotrexate LPF, Methotrexate Methylaminopterin, Methotrexatum, Metotrexato, Metrotex, Mexate, Mexate-AQ, MTX, Novatrex, Rheumatrex, Texate, Tremetex, Trexeron, Trixilem, WR-19039, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Navitoclax, A-855071.0, ABT-263, BcI-2 Family Protein Inhibitor ABT-263, Nelarabine, 2-Amino-6-methoxypurine arabinoside, 506U78, Arranon, Compound 506U78, GW506U78, Pegaspargase, L-Asparaginase with Polyethylene Glycol, Oncaspar, Oncaspar-IV, PEG-Asparaginase, PEG-L-Asparaginase, PEG-L-Asparaginase (Enzon - Kyowa Hakko), PEGLA, Polyethylene Glycol L-Asparaginase, Polyethylene Glycol-L-Asparaginase, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Thioguanine, 2-Amino 6MP, 2-Amino-1,7-dihydro-6H-purine-6-thione, 2-Amino-6-mercaptopurine, 2-Amino-6-purinethiol, 2-Aminopurin-6-thiol, 2-Aminopurine-6(1H)-thione, 2-Aminopurine-6-thiol, 2-Aminopurine-6-thiol Hemihydrate, 2-Mercapto-6-aminopurine, 6-Amino-2-mercaptopurine, 6-Mercapto-2-aminopurine, 6-Mercaptoguanine, 6-TG, 6H-Purine-6-thione, 2-amino-1,7-dihydro- (9CI), BW 5071, Lanvis, Tabloid, Thioguanine Hemihydrate, Thioguanine Hydrate, Tioguanin, Tioguanine, Wellcome U3B, WR-1141, X 27, Venetoclax, ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta, Venclyxto, Vincristine, LCR, Leurocristine, VCR, Vincrystine, X-Ray Imaging, Conventional X-Ray, Diagnostic Radiology, Medical Imaging, X-Ray, Plain film radiographs, Radiographic Imaging, Radiographic imaging procedure (procedure), Radiography, RG, Static X-Ray, X-Ray

National Cancer Institute (NCI)

T Acute Lymphoblastic Leukemia, T Lymphoblastic Lymphoma

09/26

NCT05864742: Genetically Risk-Stratified Venetoclax, Ibrutinib, Rituximab (± Navitoclax) in Relapsed/Refractory Mantle Cell Lymphoma

Active, not recruiting

RoW

Ibrutinib, imbruvica, Venetoclax, Venclexta, Navitoclax, ABT-263, Rituximab, Rituxan

Peter MacCallum Cancer Centre, Australia

Mantle Cell Lymphoma Refractory

06/26

06/29

NCT01970956: Dabrafenib/Trametinib/Navitoclax In Braf Mutant Melanoma

Not yet recruiting

1/2

Navitoclax, ABT-263, Dabrafenib, GSK2118436, GSK2118436A (free base), Tafinlar, Trametinib, GSK1120212, JTP-74057, JTP-78296, JTP-75303, Mekinist

Massachusetts General Hospital, National Cancer Institute (NCI)

BRAF Mutant Melanoma, Solid Tumors

01/17

09/20

NCT02079740: Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors

Active, not recruiting

1/2

Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Navitoclax, A-855071.0, ABT-263, BcI-2 Family Protein Inhibitor ABT-263, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Trametinib, GSK 1120212, GSK-1120212, GSK1120212, JTP-74057, MEK Inhibitor GSK1120212

National Cancer Institute (NCI)

Metastatic Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm

12/22

03/25

NCI-2013-02103, NCT01989585: Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma

Active, not recruiting

1/2

Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Dabrafenib, BRAF Inhibitor GSK2118436, GSK 2118436, GSK 2118436A, GSK-2118436, GSK-2118436A, GSK2118436, GSK2118436A, Echocardiography, EC, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNV Scan, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Navitoclax, A-855071.0, ABT-263, BcI-2 Family Protein Inhibitor ABT-263, Pharmacological Study, Trametinib, GSK 1120212, GSK 212, GSK-1120212, GSK-212, GSK1120212, GSK212, JTP 74057, JTP-74057, JTP74057, MEK Inhibitor GSK1120212

National Cancer Institute (NCI)

Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Malignant Solid Neoplasm, Metastatic Melanoma, Unresectable Melanoma

12/25

NCT05192889: Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navitoclax

Active, not recruiting

1/2

Venetoclax, Venclextra®, ABT-199, Navitoclax, ABT-263, Dexamethasone, Decadron®, Hexadrol®, Dexameth®, Vincristine, Vincristine sulfate, Oncovin®, Calaspargase Pegol, Asparlas, Dasatinib, Sprycel®, Cytarabine, Ara-C, Cytosar-U®, Blinatumomab, Blincyto®, Methotrexate, MTX, Trexall®, amethopterin, Mercaptopurine, 6-MP, Purinethol®, Cyclophosphamide, Cytoxan®, Etoposide, VP-16, Vepesid®, Leucovorin, Folinic acid, Intrathecal Triples, ITMHA, methotrexate/hydrocortisone/cytarabine, Pegaspargase, Oncaspar®, PEG-asparaginase, PEG-L-asparaginase, Erwinia asparaginase, Erwinase®, Radiation, Irradiation

St. Jude Children's Research Hospital, AbbVie

Refractory Acute Lymphoblastic Leukemia, Relapsed Acute Lymphoblastic Leukemia

06/24

03/25

22P.205, NCT05564650: Evaluating Navitoclax After Failure of Standard Treatments of Azacitidine or Decitabine and Venetoclax in Patients With Aggressive Myelodysplastic Syndrome

Recruiting

1/2

Navitoclax, 923564-51-6, A-855071.0, ABT-263, BcI-2 Family Protein Inhibitor ABT-263, Venetoclax, 1257044-40-8, 4-(4-((2-(4-Chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl)methyl)piperazin-1-yl)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)-2-(1H-pyrrolo(2,3-b)pyridin-5-yloxy)benzamide, ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta, Venclyxto, Decitabine, 2'-Deoxy-5-azacytidine, 2353-33-5, 4-Amino-1-(2-deoxy-beta-D-erythro-pentofuranosyl)-1,3,5-triazin-2(1H)-one, 5-Aza-2'-deoxycytidine, 5-Aza-2'deoxycytidine, 5-Aza-2-deoxycytidine, 5-Azadeoxycytidine, Dacogen, Decitabine for Injection, Deoxyazacytidine, Dezocitidine, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Quality of Life Assessment

Thomas Jefferson University, AbbVie

Myelodysplastic Syndrome, Recurrent Myelodysplastic Syndrome, Refractory Myelodysplastic Syndrome

01/25

07/25

HEM-iSMART A, NCT05740449: HEM-iSMART-A: Decitabine / Venetoclax and Navitoclax in Pediatric Patients With Relapsed or Refractory Hematological Malignancies

Withdrawn

1/2

Europe

Decitabine, Venetoclax, Navitoclax, intrathecal chemotherapy

Princess Maxima Center for Pediatric Oncology, Innovative Therapies For Children with Cancer Consortium, IBFM, Fight Kids Cancer

Acute Lymphoblastic Leukemia, in Relapse, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Refractory

10/29

NCT04480086: Safety and Tolerability Study of Mivebresib Tablet Alone or in Combination With Ruxolitinib Tablet or Navitoclax Tablet in Adult Participants With Myelofibrosis

Terminated

US, RoW

Mivebresib, Navitoclax, ABT-263, Ruxolitinib

AbbVie

Myelofibrosis (MF)

07/23

ITALLI001, NCT05054465: A Phase 1b-2 Trial to Assess Venetoclax and Navitoclax Consolidation and Post-transplant Maintenance in High-risk Patients With T-ALL

Not yet recruiting

RoW

Navitoclax, Venetoclax

Israeli Medical Association, Rabin Medical Center, Sheba Medical Center, Rambam Health Care Campus, Tel Aviv Medical Center, Soroka University Medical Center, Shaare Zedek Medical Center, Hadassah Medical Center

Acute Lymphoblastic Leukemia

08/25

08/26

NCT02143401: Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors

Active, not recruiting

Laboratory Biomarker Analysis, Navitoclax, A-855071.0, ABT-263, BcI-2 Family Protein Inhibitor ABT-263, Pharmacological Study, Sorafenib, BA4 43 9006, BAY 43 9006, BAY 43-9006, BAY 439006, BAY-43-9006, Bay-439006, BAY439006, Sorafenib Tosylate, BAY 43-9006 Tosylate, BAY 54 9085, BAY 54-9085, BAY 549085, BAY-54-9085, BAY549085, Nexavar, sorafenib

National Cancer Institute (NCI)

Cirrhosis, Hepatitis B Infection, Hepatitis C Infection, Metastatic Malignant Solid Neoplasm, Recurrent Hepatocellular Carcinoma, Recurrent Malignant Solid Neoplasm, Refractory Malignant Neoplasm, Stage IV Hepatocellular Carcinoma AJCC v7, Unresectable Solid Neoplasm

11/22

05/25

NCT05222984: Navitoclax, Venetoclax, and Decitabine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Previously Treated with Venetoclax

Active, not recruiting

Decitabine, 5-Aza-2'-deoxycytidine, Dacogen, Decitabine for Injection, Deoxyazacytidine, Dezocitidine, Navitoclax, A-855071.0, ABT-263, BcI-2 Family Protein Inhibitor ABT-263, Venetoclax, ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta, Venclyxto

City of Hope Medical Center, National Cancer Institute (NCI)

Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia

12/24

12/25

Exactis-03, NCT05358639: Combination of Olaparib and Navitoclax in Women with HGSC and TNBC

Active, not recruiting

Canada

Olaparib tablet, Lynparza, Navitoclax, ABT-263

Sunnybrook Health Sciences Centre, Exactis Innovation, Centre hospitalier de l'Université de Montréal (CHUM), Princess Margaret Hospital, Canada

High Grade Serous Carcinoma, Triple Negative Breast Cancer, Ovarian Cancer

03/25

04/25

NCT00788684: Safety Study of ABT-263 in Combination With Rituximab in Lymphoid Cancers

	P1 data (Lymphoid cancer, +rituximab)
	Dec 2010 - Dec 2011: P1 data (Lymphoid cancer, +rituximab)

Active, not recruiting

US, RoW

rituximab, Rituxan, ABT-263, navitoclax

AbbVie, Genentech, Inc.

CD20-Positive Lymphoid Malignancies, Chronic Lymphoid Leukemia, Hematological Malignancies, Non-Hodgkin's Lymphoma

01/25

NCT04454658: Safety and Tolerability Study of Oral ABBV-744 Tablet Alone or in Combination With Oral Ruxolitinib Tablet or Oral Navitoclax Tablet in Adult Participants With Myelofibrosis

Active, not recruiting

Europe, Japan, US, RoW

ABBV-744, Navitoclax, ABT-263, Ruxolitinib

AbbVie

Myelofibrosis (MF)

11/24

NCT02520778: Osimertinib and Navitoclax in Treating Patients With EGFR-Positive Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer

Completed

Navitoclax, A-855071.0, ABT-263, BcI-2 Family Protein Inhibitor ABT-263, Osimertinib, AZD 9291, AZD-9291, AZD9291, Mereletinib

National Cancer Institute (NCI)

Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Stage III Lung Non-Small Cell Cancer AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7, Stage IIIB Lung Non-Small Cell Cancer AJCC v7, Stage IV Lung Non-Small Cell Cancer AJCC v7

10/22

12/23

NCT04041050: A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm

Active, not recruiting

Europe, Japan, US, RoW

Navitoclax, ABT-263, Ruxolitinib, Celecoxib, Celebrex

AbbVie

Myeloproliferative Neoplasm

01/25

NCT05455294: Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid Neoplasms

Active, not recruiting

Navitoclax, ABT-263, Venetoclax, Venclexta, Decitabine, Dacogen

Jacqueline Garcia, MD, AbbVie

Myeloid Malignancy, Myelodysplastic Syndromes, Myelofibrosis, Acute Myeloid Leukemia, Myeloproliferative Neoplasm

12/24

12/26

NCT06007911: Venetoclax-Navitoclax With Cladribine-based Salvage Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Withdrawn

Navitoclax Dose Level -1, ABT-263, Navitoclax Dose Level 0, Navitoclax Dose Level 1, Navitoclax Dose Level 2, Venetoclax Dose Level -1, Venclexta, Venetoclax Dose Levels 0 to 2, Cladribine, Mavenclad, Leustatin DSC, Cytarabine (Cladribine Low Dose Cytarabine Backbone), ara-C, Cytarabine (CLAG-M Backbone), Mitoxantrone, Novantrone, Granulocyte Colony-Stimulating Factor, G-CSF, filgrastim, Neupogen

Medical College of Wisconsin

Relapsed Adult AML, Refractory AML

12/25

04/27

NCT03592576: Expanded Access to Navitoclax

No Longer Available

N/A

Navitoclax, ABT-263, Venetoclax, Venclexta, ABT-199, GDC-0199

AbbVie

Myelofibrosis, Acute Lymphocytic Leukemia (ALL), Lymphoblastic Lymphoma

NCT05215405: Expanded Access Program of Venetoclax and Navitoclax for Pediatric Patients With Relapsed or Refractory ALL or LL

Available

N/A

Venetoclax, ABT-199, Navitoclax, ABT-263

Kathleen Ludwig

Relapsed Childhood ALL, Relapsed Childhood Lymphoblastic Lymphoma



	Diseases Companies Products Productz Mechanisms of Action Sites